|
1
|
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo.
|
Blood
|
2006
|
4.46
|
|
2
|
Reciprocal effects of STAT5 and STAT3 in breast cancer.
|
Mol Cancer Res
|
2009
|
1.72
|
|
3
|
The amino terminal and E2F interaction domains are critical for C/EBP alpha-mediated induction of granulopoietic development of hematopoietic cells.
|
Blood
|
2003
|
1.51
|
|
4
|
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
|
Cancer Biol Ther
|
2011
|
1.26
|
|
5
|
Microtubule-targeted chemotherapeutic agents inhibit signal transducer and activator of transcription 3 (STAT3) signaling.
|
Mol Pharmacol
|
2010
|
1.12
|
|
6
|
STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6.
|
Mol Cell Biol
|
2013
|
1.09
|
|
7
|
Pyrimethamine inhibits adult polycystic kidney disease by modulating STAT signaling pathways.
|
Hum Mol Genet
|
2011
|
1.09
|
|
8
|
Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.
|
Mol Cancer Ther
|
2014
|
1.09
|
|
9
|
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
|
Clin Cancer Res
|
2011
|
0.93
|
|
10
|
STAT signaling in the pathogenesis and treatment of myeloid malignancies.
|
JAKSTAT
|
2012
|
0.92
|
|
11
|
Discovery and characterization of novel mutant FLT3 kinase inhibitors.
|
Mol Cancer Ther
|
2010
|
0.84
|